PT  - JOURNAL ARTICLE
AU  - Liyan Zhang
AU  - Lin Shen
AU  - Yuhan Lu
AU  - Jing Xue
TI  - Cancer immunotherapy and toxic epidermal necrolysis
AID  - 10.1136/bmjspcare-2019-002135
DP  - 2020 Sep 01
TA  - BMJ Supportive & Palliative Care
PG  - 314--315
VI  - 10
IP  - 3
4099  - http://spcare.bmj.com/content/10/3/314.short
4100  - http://spcare.bmj.com/content/10/3/314.full
SO  - BMJ Support Palliat Care2020 Sep 01; 10
AB  - Objectives Immunotherapy has come to play an increasingly important role in cancer treatment. Accordingly, immune-related adverse events (irAEs) have drawn considerable attention. In this case, a young female patient developed immune-related toxic epidermal necrolysis (TEN). The same irAEs have been rarely reported in previous studies. In this study, we describe the treatment and care methods used in this case in detail in order to provide a reference for clinical practice.Methods After being diagnosed with TEN, the patient accepted systemic glucocorticoid therapy, timely care of skin and mucous membranes, nutrition support, antiacid therapy, anti-inflammatory, analgesics and other supportive measures.Results The patient’s skin recovered completely, and no serious adverse outcomes, such as secondary infection or multiple organ failure, occurred during treatment.Conclusion Medical staff should be able to identify the performance of rare irAEs such as TENs and actively explore comprehensive treatments to ensure patient safety and avoid adverse outcomes.